IL10 inversely correlates with the percentage of CD8+ cells in MDS patients  by Lopes, Matheus Rodrigues et al.
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a  b  s  t  r  a  c  t
The  role of the  immune  system  in  myelodysplastic  syndrome  (MDS)  progression  has  been  widely
accepted,  although  mechanisms  underlying  this  immune  dysfunction  are  not  clear.  CD4+ and  CD8+ lym-
phocyte  proﬁles  in  the peripheral  blood  of  MDS  patients  were  evaluated  and  correlated  with  clinical
characteristics,  the  expression  of FOXP3  and  the anti-inﬂammatory  cytokines  IL10,  TGFˇ1  and  CTLA4.  IL10vailable online 28 February 2013
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expression  inversely  correlated  with  the  percentage  of  CD8+ cells and  was  higher  in high-risk  MDS. Our
ﬁndings  provide  further  evidence  for the  role  of  T  cell-mediated  IL10  production  in  MDS  and  strengthen
the  idea  of distinct  cytokine  proﬁles  in  low  and  high-risk  MDS.
© 2013 Elsevier Ltd. Open access under the Elsevier OA license. mmune  System
. Introduction
Myelodysplastic syndrome (MDS) is characterized by an
ncreased programmed cell death of bone marrow (BM) cells, both
lonal and nonclonal precursors, which contributes to ineffective
ematopoiesis and peripheral cytopenias [1–5]. Although the com-
lex pathogenesis of MDS  remains poorly deﬁned, several studies
ndicate a role for the immune system in the progression of early
DS to the advanced stage [6,7]. Low-risk MDS  is characterized
y excessive apoptosis in the BM and by an autoimmune disease-
ike proﬁle; whereas advanced MDS  is distinguished by immune
vasion, lower apoptosis and secondary DNA damage, facilitating
he progress into acute leukemia [7,8]. Immunosuppressive and
mmunomodulatory therapeutics have presented favorable results,
uch as abrogation of transfusion dependence for a subset of the
atients [8–12].
Although regulatory (Tregs) and cytotoxic T cells are reported to
e modulated during the course of MDS  [13], the exact mechanism
y which these cells contribute to MDS  progression is not yet clear.
ow numbers of Tregs in low-risk MDS  are associated with T cell
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Open access under the Elsevier OA license. cytotoxicity of BM precursor cells, whereas higher frequencies of
Tregs in high-risk MDS  result in a suppression of immune response
[8,14,15].
In an attempt to better understand the role of the immune sys-
tem in MDS, we  evaluated CD4+ and CD8+ lymphocyte proﬁles
in the peripheral blood of MDS  patients. These data were corre-
lated with clinical characteristics, the expression of FOXP3 and the
anti-inﬂammatory cytokines, IL10, TGFˇ1 and CTLA4.
2. Materials and methods
2.1.  Patients and healthy donors
Peripheral  blood samples, collected from 49 patients with MDS  and 29 unrelated,
random,  and healthy individuals (median age = 39, range, 28–60), were analyzed. All
patients that attended the clinic between 2010 and 2011, with a conﬁrmed diagnosis
of MDS  and untreated at the time of the study were included. All healthy controls
and patients provided informed written consent and the study was approved by
the ethics committee of the University of Campinas. Patients’ characteristics are
described in Table 1.
2.2.  Peripheral blood analyses
Hematological values were determined with a CELL-DYN Sapphire automated
hematology  analyzer (Abbott Diagnostics, Illinois, USA). Peripheral blood mononu-
clear cells (PBMC) were isolated by Ficoll-Hypaque gradient centrifugation (Sigma,
St Louis, MO). PBMC were stained with the conjugated monoclonal antibodies;
allophycocyanin  (APC) anti-CD3, ﬂuorescein isothiocyanate (FITC) anti-CD8, and
phycoerythrin (PE) anti-CD4. An FSC/SSC gate was created around the viable
lymphocyte  population for further analysis of CD3+ cells, CD3+CD4+ and CD3+CD8+
subsets. Data acquisition was performed using a FACScalibur Flow Cytometer
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Table 1
Clinical characteristics of patients.
Characteristics Value
Age y, median (range) 67 (27–89)
Sex, n (%)
Male/female 24  (49)/25 (51)
WHO  classiﬁcation, n (%)
RCUD 09  (19)
RCMD 23 (47)
RARS 8 (16)
RAEB1 7 (14)
RAEB2 2  (4)
Risk stratiﬁcation by WHOa, n (%)
Low-risk 40  (82)
High-risk 9 (18)
Cytogenetic risk group, n (%)
Good 41 (84)
Intermediate 3 (6)
Poor 2  (4)
No growth 3 (6)
Peripheral blood counts, median (range)
Hemoglobin, (g/dL) 10.5 (5.5–15.6)
White blood cell count, (×109/L) 3.58  (0.86–9.8)
Neutrophils count, (×109/L) 1.63 (0.16–6.51)
Platelet count, (×109/L) 158 (0.7–648)
Number of cytopenia, (%)
0  6 (12)
1 20 (41)
2 20 (41)
3 3 (6)
Bone marrow blasts, %, median (range) 1.5 (0–14)
RCUD indicates refractory cytopenia with unilineage dysplasia; RCMD, refractory
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cytopenia  with multilineage dysplasia; RARS, refractory anemia with ring siderob-
asts; RAEB-1/2, refractory anemia with excess blasts-1/2.
a Low-risk includes RCUD, RARS, RCMD. High-risk includes RAEB-1/2.
Becton  Dickinson, Franklin Lakes, NJ) and analyses were carried out using CellQuest
nd  BD FACSDiva software (Becton Dickinson, Franklin Lakes, NJ). The CD3+ T cells
rom PBMC were sorted using anti-CD3 monoclonal antibody and MACS® Magnetic
ell  sorting technique (Miltenyi Biotec, Bergisch Gladbach, Germany).
.3. Quantitative polymerase chain reaction
Sorted CD3+ cells were submitted to RNA extraction. Quantitative PCR (q-PCR)
as  performed in an ABI 7500 Sequence Detector System (Applied Biosystems, Fos-
er City, CA) with speciﬁc primers for FOXP3, IL10, TGFˇ1, CTLA4, and HPRT (sequences
pon  request). The relative gene expression was calculated using the equation,
−CT [16].
.4. Statistical analysisThe age-adjusted multivariate linear regression analysis was  used in order to
tudy the inﬂuence of both age and disease on all parameters evaluated in peripheral
lood [15,17]. The model included age, group (patients vs controls) and an inter-
ction  term (age vs disease status) as independent variables. The interaction term
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between  age and disease status was dropped from the ﬁnal model when not statisti-
cally signiﬁcant (P > 0.05). Two-tailed Spearman’s correlation coefﬁcient, univariate
and  stepwise multivariate models were also used. Numeric variables without nor-
mal distribution were transformed into ranks for analysis. A two-sided P < 0.05 was
considered as statistically signiﬁcant.
3. Results
3.1. Distinct proﬁles of peripheral blood lymphocytes exist in MDS
We observed a signiﬁcant decrease in lymphocyte count in the
MDS group compared to the control group after adjusting for age
(P = 0.002, Fig. 1A). This statistical difference remained after we
classiﬁed the patients into subgroups, according to WHO,  but the
decreased lymphocyte count was  more pronounced in the high-
risk MDS  (P < 0.001, Fig. 1B). Lymphopenia (<1.1 ×109 cells/L) was
found in 13 (26.5%) of 49 MDS  patients.
Age-adjusted percentages of CD3+ cells were signiﬁcantly
higher  in the MDS  group (P = 0.004, Fig. 2A). Analyses of the CD3+
cell subsets presented no statistical differences for CD3+CD4+ cells
(Fig. 2C), but showed a strong trend toward an increased percent-
age of CD3+CD8+ cells in the MDS  individuals (P = 0.05, Fig. 2E).
Comparisons between the subgroups of the disease showed higher
CD3+ frequencies in the high-risk, compared to the low-risk MDS
(P = 0.02, Fig. 2B), followed by higher CD3+CD4+ frequencies in the
high-risk compared to the control group (P = 0.02, Fig. 2D). The fre-
quency of CD3+CD8+ cells was  signiﬁcantly higher in the low-risk
MDS, when compared with the control group (P = 0.04, Fig. 2F).
There was no statistical difference between the MDS  and the
control groups with regard to the CD4:CD8 ratios (Fig. 2G); however
comparison among MDS  patients revealed a signiﬁcantly higher
CD4:CD8 ratio in the high-risk, compared to the low-risk groups
(P = 0.03, Fig. 2H).
We also correlated CD3+CD4+ and CD3+CD8+ cell frequencies
with clinical data (age, sex, hemoglobin, leukocyte, granulocyte,
platelet, number of cytopenias, percentage of blasts in BM,  and
karyotype risk group). Univariate analysis demonstrated that
advanced age correlated with a decreased percentage of CD3+CD8+
cells (Beta = −0.28; P = 0.037; R2 = 0.11), which was conﬁrmed by
multivariate analysis (Beta = −0.30; P = 0.024; R2 = 0.14). There was
no signiﬁcant correlation between CD3+CD4+ cell frequency and
the clinical parameters studied.
3.2. IL10 inversely correlates with the percentage of CD8+ cells
and presents higher expression in high-risk MDS
To better understand the regulation of the anti-inﬂammatory
cytokines IL10, TGFˇ1, and CTLA4, as well as FOXP3, in MDS, the
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Fig. 2. CD3+, CD3+CD4+ and CD3+CD8+ T cell proﬁles in MDS  and control groups. Multivariate regression analysis was performed with %CD3+ (A–B), %CD3+CD4+ (C–D),
%CD3+CD8+ (E–F), and log-transformed ratio of CD4:CD8 (G–H), as the dependent variables, and age and disease status as independent variables. The P value and the number
of  individuals are shown in the ﬁgure. Patients were subgrouped into low and high-risk MDS, according to WHO.
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Fig. 3. FOXP3, IL10, TGFˇ1 and CTLA4 expressions in the peripheral blood CD3+ cells of MDS  and control groups. Multivariate regression analysis was performed with the log-
transformed relative expression of FOXP3/HPRT (A-B), IL10/HPRT (C-D), TGFˇ1/HPRT (E), and CTLA4/HPRT (F) as dependent variables and age and disease status as independent
variables. Patients were subgrouped into low and high-risk MDS, according to WHO. (G) Relationship between the log-transformed relative expression of IL10/HPRT and the
frequency  of CD3+CD8+ cells in the peripheral blood of MDS  patients. Spearman’s correlation. The P value and the number of individuals are shown in the Figure.
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ranscript expressions of these genes were analyzed in periph-
ral CD3+ cells. We  observed a decrease in FOXP3 expression in
he MDS  group, when compared with the control group after
djusting for age (P = 0.009, Fig. 3A). Similar statistical differences
emained when low-risk MDS  was compared with the control
roup (P = 0.006, Fig. 3B). IL10, TGFˇ1, and CTLA4 correlated posi-
ively with FOXP3 expression, according to Spearman’s correlation
P = 0.008, r = 0.37; P = 0.04, r = 0.28; P = 0.01, r = 0.35, respectively).
econdly, there was a trend toward a lower IL10 expression in
he MDS  group, when compared with the control group (P = 0.06,
ig. 3C), probably due to the lower IL10 expression observed in
he low-risk MDS, when compared to the control group (P = 0.02,
ig. 3D). Additionally, higher levels of IL10 transcripts in the high-
isk, compared to the low-risk MDS, were observed (P = 0.01,
ig. 3D). No signiﬁcant differences in TGFˇ1 and CTLA4 expressions
ere observed (Fig. 3E-F). IL10 transcripts inversely correlated
ith CD3+CD8+ frequency in MDS  patients (Spearman r = −0.36;
 = 0.02, Fig. 3G); however, there were no correlations between the
ytokines analyzed and CD3+CD4+ frequency.
.  Discussion
There is a clear involvement of multiple myeloid cell lineages
n the MDS  clone, which results in the loss of the capacity of dif-
erentiation and apoptosis in the bone marrow, with consequent
eripheral pancytopenia in patients [18,19]. Conversely, several
tudies have shown that, in most cases of MDS, the lymphocytes
re not involved in the malignant clone [20–22]. In our study, there
as a signiﬁcant decrease in the absolute lymphocyte counts in
he peripheral blood of MDS  patients, which is in accordance with
he literature [21,23,24] and supports the immunological abnor-
alities that have been extensively described in MDS  patients.
ymphopenia in MDS  has been suggested to occur due to a decrease
n the T cell numbers, as a consequence of T cell apoptosis in the
eripheral blood of MDS  patients [23,25]; as well as a consequence
f CD19+ cell apoptosis in both the peripheral blood and bone mar-
ow of MDS  patients [21,26]. Additionally, a decreased NKT cell
umber, already described in MDS  patients [27], could contribute
o the lower absolute lymphocyte count. Further studies addressing
he absolute values of each cell type in the peripheral blood of MDS
atients could clarify which speciﬁc cells are involved in the lower
bsolute lymphocyte counts. Although our ﬁndings show that only
6.5% of patients with lymphopenia, the most prominent decrease
n lymphocyte counts was in the high-risk group, which is in agree-
ent with the preview reports [21,28].
Data presented herein show that the increase in CD3+ cell per-
entage in MDS  may  be a reﬂection of CD8+ frequency in the
ow-risk group and CD4+ frequency in the high-risk group. The
ncreased CD8+ frequency in the low-risk MDS  is in agreement with
ther studies [29–35] and supports the contribution of CD8+ cells to
he apoptosis of hematopoietic progenitors, since the early stages
f this disease are characterized by an increased apoptotic activity
7].
In contrast to previous reports demonstrating no signiﬁcant dif-
erences in the CD4+ cell frequency between patients and controls
36,37], we showed a higher CD4+ cell frequency in high-risk MDS,
ith a consequently increased CD4:CD8 ratio in this subgroup.
n fact, studies of T cell subsets in MDS  have been contradictory;
 decreased CD4:CD8 ratio in MDS  patients has been reported
15,38], while other studies have shown an increased CD4:CD8 ratio
n intermediate and high-risk MDS  [39]. It has been shown that the
nversion of the CD4:CD8 ratio is associated with the response to
mmunosuppressive therapy (IST) and is inversely correlated with
he proliferative T-cell index before IST in these patients [15]. Takenarch 37 (2013) 541– 546 545
together,  our results suggest the contribution of T CD4+ cells to the
pathophysiology of the disease.
The majority of CD4+ Treg cells present speciﬁc FOXP3 expres-
sion, a transcription factor, which is important for the development
and function of these cells [40]; however, a population of
CD8+FOXP3+ T cells has been described in several autoimmune
diseases, after allergen exposure and allogenic transplantation
[41–46]. We  found that the lower expression of FOXP3 transcripts
in the peripheral CD3+ cells of MDS  patients was  clearly due to the
lower expression of this gene in the low-risk group. The only study
that reports on CD8+ Treg cells in MDS, related no difference in the
number of CD8+ Treg cells between MDS  groups, IPSS or disease
progression [14]. Although data regarding CD4+ Treg frequency in
the low-risk MDS  patients are uncertain, mainly due to the different
ﬂow cytometry strategies used [47], our data for FOXP3 expression
support studies that report that the number of CD4+ Tregs is lower
in low-risk MDS  [7,14].
Although  IL10 and TGFˇ1 are secreted by many cell types, the
production of IL10 and TGFˇ1, as well as the expression of CTLA4,
are indications of the activation of Treg cells [40]. Our results
in CD3+ cells showed a signiﬁcant positive correlation between
the expression of these regulatory molecules and FOXP3 expres-
sion, indicating that these transcripts are derived from Treg cells.
IL10 and FOXP3 expressions were lower in the low-risk group,
compared to the control group, corroborating the hypothesis of
down-regulated Tregs in low-risk MDS  [7].
A signiﬁcant increase in IL10 expression was  observed in high-
risk, compared to low-risk MDS, which is in agreement with the
measurement of IL10 concentrations in serum, described by Kor-
dasti et al. [48]. Interestingly, we  observed an inverse correlation
between CD8+ cell frequency and IL10 expression, supporting data
describing the recruitment of CD8+ cells in an inverse relationship
with the levels of Tregs in the bone marrow of MDS  patients [49].
IL10 is thought to contribute to the immune suppressive milieu,
by inhibition of antigen presentation, cytokine expression and T
helper cell functions [50,51], all features of the immune evasion
that is characteristic of high-risk MDS  [7]. We  postulate that IL10,
secreted by Tregs, may  have a role in the prevention of MDS  clone
elimination, with a consequent role in MDS  progression.
In conclusion, our ﬁndings provide further evidence for Treg
deregulation in low-risk MDS; and most importantly, add new
insight into the role of T cell-mediated IL10 production in MDS  and
strengthen the idea of distinct cytokine proﬁles in low and high-risk
MDS.
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